Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study
FY 2022-23
Summary
Bipolar disorder (BD) is a severe and persistent mental illness with a lifetime prevalence of 2-3%, with over one-third of BD patients suffering from treatment resistant BD (TRBD). Pharmacotherapy and psychotherapy remain the first line treatment for BD, though high rates of treatment resistance, relapse, and negative side effects are major barriers to effective treatment of BD. It is evident that current treatment options are not as effective as they ideally would be, and highlights the need for more effective treatments of BD. The current understanding of the neurobiological mechanisms of BD and TRBD is limited, and presents a major obstacle in identifying new, more effective treatments.
Evidence from both open-label and randomized clinical trials has demonstrated that psilocybin, a naturally occurring psychedelic, can produce rapid, robust, and potentially prolonged antidepressant effects. In addition to these clinical benefits, psilocybin-based research has allowed for a greater level of understanding of the mechanisms involved in mood disorders. Current evidence suggests that psilocybin may allow patients to confront and process negative emotions instead of mitigating them. A greater understanding of the neurobiological effects of psilocybin has tremendous potential for identifying new TRBD treatment targets. The results of this study will provide valuable new insight into and improve our understanding of the neurobiology of TRBD while also providing robust evidence for the antidepressant effects and clinical outcomes of psilocybin-assisted psychotherapy for TRBD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486577
Name
Chen-Li David C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bipolar Depression; Depression; Functional Magnetic Resonance Imaging; Mood Disorder; Neurobiology; Pharmacotherapy; Psilocybin; Psychedelics; Psychopharmacology; Treatment Resistant
Abstract
Bipolar disorder (BD) is a severe and persistent mental illness with a lifetime prevalence of 2-3%, with over one-third of BD patients suffering from treatment resistant BD (TRBD). Pharmacotherapy and psychotherapy remain the first line treatment for BD, though high rates of treatment resistance, relapse, and negative side effects are major barriers to effective treatment of BD. It is evident that current treatment options are not as effective as they ideally would be, and highlights the need for more effective treatments of BD. The current understanding of the neurobiological mechanisms of BD and TRBD is limited, and presents a major obstacle in identifying new, more effective treatments.
Evidence from both open-label and randomized clinical trials has demonstrated that psilocybin, a naturally occurring psychedelic, can produce rapid, robust, and potentially prolonged antidepressant effects. In addition to these clinical benefits, psilocybin-based research has allowed for a greater level of understanding of the mechanisms involved in mood disorders. Current evidence suggests that psilocybin may allow patients to confront and process negative emotions instead of mitigating them. A greater understanding of the neurobiological effects of psilocybin has tremendous potential for identifying new TRBD treatment targets. The results of this study will provide valuable new insight into and improve our understanding of the neurobiology of TRBD while also providing robust evidence for the antidepressant effects and clinical outcomes of psilocybin-assisted psychotherapy for TRBD.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chen-Li, David C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~